Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-08-30
1994-09-20
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
564 82, C07D47104, A61K 31445
Patent
active
053489608
ABSTRACT:
A series of 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones having enhanced water solubility bioavailability and metabolic stability is disclosed in the Formula I ##STR1## wherein R.sup.1 is H, or C.sub.1 -C.sub.4 lower alkyl;
REFERENCES:
patent: 3932407 (1976-01-01), Beverung, Jr. et al.
patent: 4256748 (1981-03-01), Chodnekar et al.
patent: 4490371 (1984-12-01), Jones et al.
patent: 4668686 (1987-05-01), Meanwell et al.
patent: 4701459 (1987-10-01), Meanwell et al.
patent: 4775674 (1988-10-01), Meanwell et al.
patent: 4943573 (1990-07-01), Meanwell
S. Seiler et al., "Imidazoquinoline Derivatives: Potent Inhibitors of Platelet cAMP Phosphodiesterase which Elevate cAMP Levels and Activate Protein Kinase in Platelets," Throm. Res., 672: 31-42 (1991).
Kozak, et al, Bull. Intern. Acad. Polanaise, 1930A: 423-438 (Chem. Abs. 25, 5400)(1990).
J. S. FLeming, et al., New Drugs Annual: Cardiovascular Drugs, Raven Press, 277-204 (1983).
J. S. Fleming, et al., "Antithrombotic Activity of BMY 43351, a New Imiadzoquinoline with Enhanced Aqueous Solubility," Throm. Res., 63, 145-155 (1991).
Ikeda, et al., "Comparison of the Inhibitory Effects of Cilostazol, Acetylsalicylic Acid and Ticlopidine on Platelet Functions ex vivo," Arzeim.-Forsch./Drug Res., 37: 563-566 (1987).
Tanaka, et al., "Effects of a Selective Inhibitor of Cyclic AMP Phosphodiesterase on the Pial Microcirculation in Feline Cerebral Ischemia," Stroke, 20: 668-673 (1989).
Tanaka, et al., "Effects of Cilostazol, a Selective cAMP Phosphodiesterase Inhibitor on the Contraction of Vascular Smooth Muscle," Pharmacology, 36: 313-320 (1988).
Wantanabe, et al., Arzneim.-Forsch./Drug. Res., 36: 1022-1024 (1986).
Shimizu, et al., "Physico-chemical Properties and Stability of Cilostazol," Arzneim.-Forsch./Drug Res., 35 (II): 1117-1123 (1985).
Akiyama, et al., "The Absorption, Distribution and Excretion of a New Antithrombotic and Vasodilating Agent, Cilostazol, in Rat, Rabbit, Dog and Man," Arzeim.-Forsch./Drug Res., 35 (II): 1124-1132 (1985).
Akiyama, et al., "The Metabolism of a New Antithrombotic and Vasodilating Agent, Cilostazol, in Rat, Dog and Man," Arzeim.-Forsch/Drug Res., 35 (II): 1133-1140 (1985).
Usuda, et al., "The Localization of a New Antithrombotic Agent, Cilostazol, in CHO-K1 Cells as Demonstrated by Autoradiography," Arzeim.-Forsch./Drug Res., 35 (II): 1141-1143 (1985).
Kimura, et al., "Effect of Cilostazol on Platelet Aggregation and Experimental Thrombosis," Arzeim.-Forsch/Drug Res., 35 (II): 1144-1149 (1985).
Kawamura, et al., "Effect of Cilostazol, a New Antithrombotic Drug, on Cerebral Circulation," Arzneim.-Forsch/Drug Res., 35 (II): 1149-1154 (1985).
Kawamura, et al., "Effect of Cilostazol, a New Antithrombotic Drug, on an Experimental Model of Peripheral Circulation Insufficiency," Arzneim.-Forsch./Drug Res., 35 (II): 1154-1156 (1985).
Shintani, et al., "General Pharmacological Properties of Cilostazol, a New Antithrombotic Drug, Part I," Arzneim-Forsch/Drug Res., 35 (II): 1157-1162 (1985).
Shintani, et al., "General Pharmacological Properties of Cilostazol, a New Antithrombotic Drug, Part II," Arzneim.-Forsch/Drug Res., 35 (II): 1163-1172 (1985).
Niki, et al., "Phase I Study of Cilostazol," Arzneim.-Forsch./Drug Res., 35 (II): 1173-1185 (1985).
Yasunaga, et al., "Clinical Effects of Oral Cilostazol on Suppression of Platelet Function in Patients with Cerebrovascular Disease," Arzneim-Forsch/Drug Res., 35 (II): 1186-1188 (1985).
Yasunaga, et al., "Antiaggregatory Effects of Oral Cilostazol and Recovery Platelet Aggregability in Patients with Cerebrovascular Disease," Arzneim.-Forsch/Drug Res., 35 (II): 1189-1192 (1985).
Kobayashi, et al., "Long-Term Effect of Cilostazol on Cerebral Blood Flow in Chronic Cerebral Infarction," Arzneim.-Forsch./Drug Res., 35 (II): 1193-1197 (1985).
Yasuda, et al., "Hemodynamic Effect of Cilostazol on Increasing Peripheral Blood Flow in Arteriosclerosis obliterans," Arzneim.-Forsch/Drug Res., 35 (II): 1198-1200 (1985).
Ohashi, et al., "Thermographic Evaluation of the Hemodynamic Effect of the Antithrombotic Drug Cilostazol in Peripheral Arterial Occlusion," Arzneim.-Forsch/Drug Res., 35 (II): 1203-1208 (1985).
Kamiya, et al., "Hemodynamic Effects of the Antithrombotic Drug Cilostazol in Chronic Arterial Occlusion in the Extremities," Arzneim.-Forsch./Drug Res., 35 (II): 1201-1203 (1985).
Hewawasam Piyasena
Meanwell Nicholas A.
Almaula Prabodh I.
Bristol--Myers Squibb Company
Cintins Marianne M.
Spivack Phyllis G.
LandOfFree
Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2429889